article thumbnail

WebMD Bolsters Patient Engagement Offerings Through New Acquisition

MedCity News

WebMD acquired the operating assets of Healthwise, a nonprofit provider of health education content and patient engagement tools. The deal follows another acquisition WebMD made in the patient engagement space in 2020.

Patients 314
article thumbnail

It’s Time for Healthcare To Embrace Patient-Friendly Language

MedCity News

If organizations present medical records, cost data, and descriptions of billing codes to patients without providing context or stripping out medical jargon, then the information is potentially subject to regulatory penalties. That means providing more patient-friendly terminology is more than just a compliance checkbox.

Patients 316
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Report: Firearm-related Injuries Cost US Healthcare $1B Annually

MedCity News

In just 2020, deaths from gun violence cost the U.S. healthcare system $290 million, or about $6,400 per patient, according to a report from the Commonwealth Fund. These costs are mostly covered by Medicaid and other government insurance programs.

article thumbnail

The New Opportunity to Help Rare Disease Patients

MedCity News

In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.

Patients 245
article thumbnail

GSK's ViiV explores novel pathway to bring long-acting HIV med Cabenuva to tough-to-treat patients

Fierce Pharma

GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.

Patients 226
article thumbnail

Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa

Fierce Pharma

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday.

FDA 207
article thumbnail

ReKlame Health Expands Its Culturally Competent Behavioral Healthcare Model to 2 More States

MedCity News

ReKlame Health launched in 2020 to provide affordable, culturally competent behavioral healthcare to Black and Brown communities in New York. On Monday, the startup announced it is now serving patients in two additional states — New Jersey and Florida.